Publication: Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.
Authors: Vlachogiannis G, Valeri N, et. al
Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from metastatic, heavily pretreated colorectal and gastroesophageal cancer patients recruited in phase 1/2 clinical trials. Phenotypic and genotypic profiling of PDOs showed a high degree of similarity to the original patient tumors. Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses. We compared responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials. Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
Science Translational Medicine 09 Oct 2019: Vol. 11, Issue 513, eaay2574 DOI: 10.1126/scitranslmed.aay2574
Curr Opin Genet Dev. 2019 Mar 4;54:7-11. doi: 10.1016/j.gde.2019.02.003
Commun Biol. 2019 Feb 25;2:78. doi: 10.1038/s42003-019-0305-x. eCollection 2019.
Ann Surg Oncol. 2019 Jan;26(1):139-147. doi: 10.1245/s10434-018-7008-2. Epub 2018 Nov 9.
Nature 561, S48-S49 (2018); doi: 10.1038/d41586-018-06708-3
Human Molecular Genetics, Volume 27, Issue R2, 01 August 2018, Pages R99–R107
Subscribe to our newsletter
Stay up-to-date on the latest advancements in 3D cell culture technology